Octant is a therapeutics company pioneering a new type of small molecule drug discovery by using massive experimentation in human cells via its Navigator platform, which integrates synthetic biology, high-throughput chemistry, and AI/ML. The platform models how target proteins interact within cells — including signaling, transcription, and trafficking — rather than simply binding isolated proteins. Octant focuses on rare diseases and oncology driven by protein misfolding.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2022
May 2020
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biotech venture firm and therapeutics accelerator that invests at seed stage and acts as a drug d...
